Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada.…
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company’s PrenatalDetect RHD test (CPT 0536U) at…
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical trial, a key milestone in the company’s efforts to bring a targeted next-generation…
“I took over as the new CEO of Devyser on August 4th and it has been an exciting and eventful time. We are continuing to launch unique products and sign cooperation agreements with major…
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its next-generation sequencing (NGS) based CFTR assay is now compliant under the European In Vitro…
On Wednesday November 5 at 9:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q3 2025 report (which will have been published earlier on November 5 at 07:30 a.m.…
An Extraordinary General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Monday, 22 September 2025 at Bränningevägen 12, 120 54 Årsta. The main…
“A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs…
On Tuesday July 22 at 9:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q2 2025 report (which will have been published earlier on July 22 at 07:30 a.m.…
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed…
